Ocugen will report Q3 2026 results on 4 November 2026, a checkpoint on its OCU400 timeline and Roots licensing deal.

BioNTech plans to amend Phase 3 ROSETTA Breast-01 to test pumitamig with Gilead's Trodelvy instead of chemotherapy; the change needs regulatory approval.

MoffettNathanson trimmed its target but kept buy; Needham downgraded to hold. Netflix cut its 2026 ad revenue forecast to ...

Western Digital rose 3.9% Wednesday as BofA raised its target to $800 and Morgan Stanley cut to $643, both keeping bullish ...

Bernstein analyst James Hooper reaffirmed a Buy rating on BASF on Tuesday, holding his price target at 61 euros. The ...

About 2,000 trade unionists rallied in Strasbourg against the EU Inc draft, demanding binding guarantees for workers' rights as a committee vote slipped to 5 November.

The Nasdaq 100's 1.1% rebound to 29,529.34 points offered traders some relief after a bruising selloff, but the advance found no takers in Asia, where chip stoc ...

Plug Power's stock closed Monday at 1.23 euros, hovering just above its 52-week low of 1.21 euros — a valuation that says more about the market's mood on hydrog ...

Ocugen confirmed 140 patients enrolled in the liMeliGhT Phase 3 trial of OCU400, with the primary endpoint now measured using ...

Lenzing's fully guaranteed EUR 300 million rights issue is set to close on 20 October, but Berenberg's downgrade highlights ...

Rocket Lab rose 3% as ARK Invest bought 168,633 shares and Cantor Fitzgerald kept its $122 target, even after Neutron's maiden flight slipped to 2027.

Caterpillar pledged up to $10M for North Carolina workforce training, kept its $1.63 dividend, and faces a margin test in Oct ...